Logo
DCA

Smith & Nephew plc

eurostoxx600
SN.LHealthcareMedical Devices
1 091,50 £GB
-0.32%
Dernier cours
1 091,50 £GB
2026-06-02
Variation 24h
-0.32%
-3.50 GBp
Volume
1,8 M
Titres échangés
Fiabilité des données
Forte
9722 points (38 ans)

Évolution du cours

Lancer une simulation avec cet actif

SN.L

Paramètres globaux

Données disponibles du 01/07/1988 au 02/06/2026

Analyse Fondamentale

New
CAGR (5y)
5.73%
Revenue Growth
Net Margin
10.14%
Profitability
ROE
11.82%
Return on Equity
Debt / EBITDA
2.17
Solvency
PEG Ratio
1.23
Valuation vs Growth
Rev. Growth (TTM)
7.40%
Current Trend
Focus technique
SN.L
Volatilité 30j
25.82%
Écart MA50
-6.96%
Écart MA200
-14.05%
Écart ATH
-45.15%
Momentum 3M
-20.42%
Score de risque
N/A

Volatilité modérée. Momentum neutre.

À propos de Smith & Nephew plc

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Investir cet actif
Acheter via Saxo Banque
🏦Courtier régulé (AMF)
🌍Accès marchés globaux
📈Outils professionnels

Lien commercial. Investir comporte des risques.

Analyse Technique & Risque

Metrics Clés

CAGR4.96%
Volatilité25.82%
Max Drawdown-29.32%

Momentum : SN.L

Indicateur synthétique
PEURNEUTREAVIDITÉ
42
Fear

Analyse Risque

VaR (95%)-2.28%
Santé DCA
95/100

Historique récent (60 jours)

DateClôtureVolume
2026-06-021 091,50 £GB1 782 129
2026-06-011 095,00 £GB0
2026-05-291 111,00 £GB4 507 231
2026-05-280,00 £GB4 075 486
2026-05-271 126,50 £GB1 925 415
2026-05-261 133,50 £GB1 712 785
2026-05-221 138,00 £GB2 952 138
2026-05-211 142,50 £GB0
2026-05-201 145,00 £GB3 014 416
2026-05-191 157,00 £GB2 584 857
2026-05-181 122,00 £GB551
2026-05-151 112,00 £GB2 165 122
2026-05-141 104,00 £GB4 380 955
2026-05-131 102,50 £GB2 385 422
2026-05-121 103,00 £GB6 758 286
2026-05-111 073,50 £GB2 505 185
2026-05-081 093,00 £GB2 316 223
2026-05-071 114,00 £GB2 928 242
2026-05-061 117,50 £GB5 696 463
2026-05-051 159,00 £GB3 265 388
2026-05-011 147,00 £GB1 316 259
2026-04-301 137,00 £GB7 577 730
2026-04-291 132,50 £GB1 814 681
2026-04-281 157,50 £GB1 540 747
2026-04-271 182,00 £GB3 052 283
2026-04-241 158,00 £GB2 709 243
2026-04-231 184,50 £GB2 592 677
2026-04-221 214,50 £GB2 351 011
2026-04-211 221,00 £GB1 283 466
2026-04-201 262,50 £GB3 154 258
2026-04-171 268,00 £GB2 203 810
2026-04-161 252,00 £GB1 059 655
2026-04-151 262,50 £GB3 051 532
2026-04-141 263,00 £GB2 302 571
2026-04-131 242,00 £GB1 833 030
2026-04-101 246,50 £GB2 179 366
2026-04-091 227,50 £GB2 690 866
2026-04-081 226,50 £GB3 883 492
2026-04-071 193,00 £GB8 700 253
2026-04-021 207,50 £GB4 905 965
2026-04-011 199,50 £GB1 573 710
2026-03-311 185,00 £GB1 706 437
2026-03-301 200,50 £GB1 572 991
2026-03-271 193,00 £GB2 133 753
2026-03-261 195,50 £GB1 633 310
2026-03-251 209,50 £GB1 128 628
2026-03-241 205,00 £GB5 705 998
2026-03-231 187,50 £GB6 420 770
2026-03-201 200,50 £GB5 897 866
2026-03-191 205,50 £GB2 037 386
2026-03-181 251,50 £GB1 790 990
2026-03-171 251,50 £GB1 564 472
2026-03-161 241,50 £GB900 807
2026-03-131 248,00 £GB1 741 482
2026-03-121 240,50 £GB3 115 096
2026-03-111 243,50 £GB2 712 852
2026-03-101 232,00 £GB2 853 767
2026-03-091 252,00 £GB2 288 713
2026-03-061 284,50 £GB2 230 477
2026-03-051 306,00 £GB2 700 403

Derniers Dividendes

DateMontant
2026-03-26+18,07 £GB
2025-10-02+11,26 £GB
2025-03-27+17,48 £GB
2024-10-03+11,10 £GB
2024-03-28+18,49 £GB
2023-10-05+11,89 £GB
2023-03-30+18,38 £GB
2022-09-29+12,91 £GB
2022-03-31+18,40 £GB
2021-09-30+10,50 £GB
2021-04-01+16,62 £GB
2020-10-01+11,07 £GB
2020-04-02+18,66 £GB
2019-10-03+11,50 £GB
2019-04-04+16,99 £GB
2018-10-04+10,67 £GB
2018-04-05+16,24 £GB
2017-10-05+9,34 £GB
2017-03-30+14,42 £GB
2016-10-06+10,08 £GB

Actifs Relatifs